IFF refuses to estimate performance, the prospects of the flavor and fragrance?
On August 10, the International Flavours and Fragrances Corporation (IFF) announced that it would raise its quarterly dividend, but said that due to the uncertainties caused by the epidemic, it would temporarily not release its full-year performance guidance, indicating that the outlook for the global flavors and fragrances industry is still unpredictable.
On the 10th, IFF announced when it announced its second-quarter results that the company’s board of directors had authorized a 3% increase in the quarterly dividend for common stock, or $0.02, to $0.77 per share. The dividend for the second quarter will be paid on October 5 for shareholders who are still on the register as of September 24. This is the 11th consecutive year that IFF has increased its quarterly dividend.
At the same time, IFF said that given the continued fermentation of the new crown epidemic, its final impact is still unclear. The company is currently unable to predict its full-year financial performance, so it has not issued full-year performance guidance.
Despite the blurry outlook for the industry, IFF CEO Andreas Fibig (Andreas Fibig) revealed that the company's sales have improved in July. "With the relaxation of the new crown restrictions and the suspension of production and business measures, people’s mobility has increased. We saw signs of improvement in July, and sales have achieved a growth of no more than 3%-this is a significant improvement, since the second quarter. Turning point."
2026-08-19
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Asahi Kasei, Mitsui Chemicals, and Mitsubishi Chemical Agree in Principle to Establish New Joint Venture to Restructure Ethylene Production in Western Japan
-
Novo Nordisk Enters High-Stakes Bidding War with Pfizer for Metsera
-
Pfizer Seen Holding Strategic Edge in Bidding Battle for Metsera
-
Cipla CEO Calls Tirzepatide a High-Science Product with Strong Market Outlook
-
April Chemical Industry Shutdown Wave Arrives: Maintenance Plans Reflect Deep Cost Anxiety Across Enterprises
-
China National Salt Industry Corporation Advances 10,000 t/y Sodium Metal Expansion Project, Industry Leader Invests Nearly RMB 100 Million
-
350 Million Yuan! Shandong Huayang Dr Chemical Industry Co., Ltd.'s Nitric Acid Expansion in Ningyang, Tai'an
-
Merck and Eisai Halt Late-Stage Trial for Liver Cancer Therapy
-
Novo Nordisk’s Oral Wegovy Wins EU Approval as Weight-Loss Competition Shifts from Injections to Pills
-
AstraZeneca Pays Up to $1.5 Billion for Global Rights to Chinese Lung Cancer Drug
Recommend Reading
-
Wanhua Chemical and Xingfa Group Jointly Develop 5.32 Billion Yuan Phosphate Mine
-
Ingredion Agrees to Acquire Tate & Lyle for $3.6 Billion, Reshaping the Global Specialty Ingredients Market
-
A Cold-Chain Crackdown in Delhi Sends a Much Bigger Message
-
China’s Approval of Pfizer’s GLP-1 Drug Signals a Sharper Obesity Race
-
“Shutdown Equals Price Hike”: TDI Market Enters a New Era of “Scarcity Games”
-
Premium Global Chemical Sourcing Requests (26 - 30 Jan, 2026)
-
Canada Issues Non-Compliance Notice to Dr. Reddy’s on Semaglutide Generic
-
Applications of Diphenyl Cyanide
-
Bottom-fishing and Replenishment Orders & Strong Raw Materials Drive Significant ABS Price Increase in January
-
Costs Rise, January PP Follows Upstream Prices